IL‐1β antagonism with the monoclonal antibody canakinumab has recently been shown to reduce recurrent events and IL‐6 levels in patients with established CAD in a large phase III clinical trial,6 thereby firmly establishing inflammatory cytokines as a therapeutic targets in CAD. The gene discussed is IL6; the disease is coronary artery disorder.